Short hairpin RNAs (shRNAs) have emerged as a novel therapeutic modality, but there is increasing concern over nonspecific effects in vivo. Here, we used viral vectors to express shRNAs against endogenous p53 in livers of conditional MYC-transgenic mice. As expected, the shRNAs silenced hepatic p53 and accelerated liver tumorigenesis when MYC was concurrently expressed. Surprisingly, various irrelevant control shRNAs similarly induced a rapid onset of tumorigenesis, comparable to carbon tetrachloride (CCl 4 ), a potent carcinogen. We found that even marginal shRNA doses can already trigger histologically detectable hepatoxicity and increased hepatocyte apoptosis. Moreover, we noted that shRNA expression globally dysregulated hepatic microRNA (miRNA) expression, and that shRNA levels and activity further increased in the presence of MYC. In MYC-expressing transgenic mice, the marginal shRNA-induced liver injury sufficed to further stimulate hepatocellular division that was in turn associated with markedly increased expression of the mitotic cyclin B1. Hence, even at low doses, shRNAs can cause low-level hepatoxicity that can facilitate the ability of the MYC oncogene to induce liver tumorigenesis. Our data warrant caution regarding the possible carcinogenic potential of shRNAs when used as clinical agent, particularly in circumstances where tissues are genetically predisposed to cellular transformation and proliferation.
IntroductIon
The MYC oncogene is known to play an important role in the pathogenesis of hepatocellular carcinoma (HCC).
1,2 MYC overexpression is thought to exert its neoplastic function by inducing autonomous cellular proliferation and growth, blocking differentiation, and causing genomic destabilization.
3-7 Previously, we have described the use of the tetracycline regulatory system to develop a conditional transgenic mouse model of MYC-induced HCC. [8] [9] [10] [11] Using this model system, we have found evidence suggesting that MYC overexpression is restrained from inducing tumorigenesis in adult-but not in embryonic or neonatal-mice, in part, through a p53-regulated mechanism. 8, 12 Here, we explored the role of p53 in liver tumorigenesis by using RNA interference (RNAi) to suppress hepatic p53 expression in adult MYC-transgenic mice. We therefore engineered potent adeno-associated virus serotype-8 (AAV-8) vectors that are known to be highly efficient in murine liver [13] [14] [15] [16] [17] [18] [19] to encode and deliver antip53 short hairpin RNAs (shRNAs). To maximize efficacy, we used self-complementary AAVs carrying double-stranded (ds) DNA genomes. During vector production, their replication arrests after a single cycle, leading to insert duplication and packaging as an inverted tandem. In transduced cells, the two copies efficiently and rapidly self-anneal, yielding markedly increased transgene expression as compared to standard single-stranded AAV vectors. The specific vector plasmid backbone we used here has been optimized with respect to stability in bacteria, by flanking the recombinant genome with packaging signals derived from two distinct AAV genotypes (AAV-2/-4; D. Grimm, L.S. Wang, J.S. Lee, T.A. Storm, and M.A. Kay, unpublished results). All vectors used in this study were bicistronic, with one cistron encoding the shRNA under a strong U6 promoter and the other a gfp transduction marker.
We previously had used our new dsAAV vector backbone to express 49 distinct shRNAs against numerous targets in murine livers, from reporter genes to hepatitis B virus. 16 The in vivo vector efficacy was very high, yielding complete liver transduction from single peripheral infusion of medium AAV doses (2 × 10 ) and use of a minimal liver-specific promoter allowed us to stably block viral gene expression in hepatitis B virus-transgenic mice, in the absence of phenotypically detectable hepatoxicity. 16, 20 We also recently used our dsAAVs to achieve safe, efficient, and stable suppression of various endogenous genes encoding fatty acid transporters in livers of adult mice. 21 Here, we report that even marginal, peripherally delivered shRNA doses can yield drastic phenotypes in the adult liver. In MYC-expressing mice, various unrelated shRNAs caused global miRNA dysregulation and low-level cytotoxicity, that in turn promoted unrestrained hepatocyte proliferation and accelerated liver tumorigenesis. Our data imply a dual functional role for MYC, by transactivating U6-shRNA expression in AAV-transduced hepatocytes, and stimulating proliferation of adjacent cells. Our study reveals a previously unknown general carcinogenic property of shRNAs in vivo. Thus they warrant further caution in the use of these promising biotherapeutics in humans.
Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice
Shelly
results
We designed and screened a panel of 10 different shRNAs for efficacy at p53 knockdown in vitro, before engineering the best two candidates into dsAAV-8 vectors (Figure 1a,b) . [13] [14] [15] [16] [17] [18] [19] For their in vivo evaluation, we then injected the following cohorts of mice (Figure 1c) : first, we infused either normal or MYC-transgenic mice with each vector at three distinct particle doses, 10 12 (high), 2 × 10 11 (mid), or 2 × 10 10 (low). The two higher doses previously had been found to be sufficient to yield complete liver transduction. 16 Among the infected MYC-transgenic mice, MYC was induced in one cohort and kept inactive in controls (MYC ON or OFF, respectively). To account for nonspecific shRNA effects, we also infused three AAV/shRNA vectors targeting genes irrelevant for HCC. Two of the vectors served as positive controls for adverse side effects, by expressing shRNAs known from our prior work to be highly toxic [25 mer against human α-1-antitrypsin (hAAT-25) or against hepatitis B virus surface antigen (sAg-25)], whereas the third expressed a nontoxic anti-hAAT 19 mer. 16 As a positive control for liver tumorigenesis, we injected MYC ON or OFF mice with carbon tetrachloride (CCl 4 ), a known and potent carcinogen. Finally, we also monitored noninjected control MYC transgenics in which MYC was either overexpressed or kept inactive (Figure 1c) .
We observed that the high-and mid-anti-p53 vector doses were lethal in all mice across all cohorts, regardless of MYC status. This was consistent with our previous findings of frequent morbidity from shRNA overdosing in murine livers in our recent study, 16 where about 50% of all tested shRNAs had killed the animals within a few weeks after injection. Gross and histological analyses of all major organs in ailing mice injected with the highor mid-p53 shRNA dose revealed that the main changes were in the liver, with chronic hepatoxicity characterized by lobular collapse and multifocal necrosis, likewise consistent with our previous observations. 16 At necropsy, there was no evidence for liver tumorigenesis in these mice (data not shown).
The outcome of infusion at the low shRNA vector dose (2 × 10 10 ) was markedly different, depending on both shRNA as well as MYC status (comprehensively summarized in Supplementary  Table S1 ). In MYC OFF mice, AAV/anti-p53 infusion was not associated with evidence of toxicity or lethality. We also observed no morbidity in MYC OFF mice treated with any of the controls (hAAT/HBV-shRNAs or CCl 4 ) (Figure 2) . In contrast, infusion of MYC ON mice with the anti-p53 shRNAs (#6 and 7 gave similar Figure 2 ). The data discussed below are based on the lowest dsAAV vector dose.
Next, we characterized our various cohorts on a molecular, gross, and histological level. First, we assayed p53 expression and AAV vector copy numbers (Figure 3a,b) . We noted an expected rapid and substantial p53 suppression following infusion of the anti-p53 vectors, compared to untreated mice or control shRNAs (Figure 3a ). Yet, in the presence of MYC, p53 mRNA levels consistently increased again at later timepoints (arrow in Figure 3a) , concurrent with HCC formation and morbidity. We inferred that this loss of p53 suppression resulted from elimination of the episomal anti-p53 shRNA-encoding AAV vectors from the rapidly dividing tumor cells. Our results were confirmed by Southern blot analyses of AAV vector copy numbers in total liver DNA (Figure 3b ). An identical gradual loss of vector DNA was also seen with the toxic control shRNAs (sAg-25 and hAAT-25; Figure 3b and data not shown).
On a gross level, we could distinguish three distinct phenotypes among the different cohorts of mice. A first group comprised MYC ON mice treated with the anti-p53 shRNA vectors: 3-4 weeks after injection, these animals developed 2.5-3.1-fold enlarged livers that exhibited diffuse carcinoma consisting of a multitude of coalescing tumor nodules (Figure 4f, compare to panels a,b) . Similarly, MYC ON mice injected with the toxic control shRNAs also rapidly developed tumors that strikingly resembled those in the anti-p53 groups [ Figure 4g , compare to panel f; results for hAAT-25 were similar (data not shown)]. Moreover, MYC ON/CCl 4 tumors were also grossly similar to shRNA-induced HCC (Figure 4h , compare to panels f,g). All these tumors were distinct in appearance from the focal tumors that were instead typical for the second group, which comprised naive and hAAT-19-injected MYC ON mice. Tumors in this second category also developed with a much greater latency of up to 5 months (Figure 4e and data not shown). Table S1) .
Like in MYC ON mice, we also could distinguish the effects of toxic and nontoxic shRNAs in the vector-treated MYC OFF cohorts. Mice injected with the nontoxic hAAT-19 shRNA maintained a histologically normal liver, as did untreated control MYC OFF mice (Figure 5b, panels A, G) . However, injection of the anti-p53 shRNAs induced multiple histological changes suggestive of hepatoxicity, including multifocal pleocellular inflammation, scattered individual cell degeneration and necrosis, and anisokaryosis ( Figure 5b , panel C; and data not shown). Likewise, MYC OFF/sAg-25 mice showed liver injury associated with small numbers of individual necrotic cells and mitoses throughout the parenchyma, and occasional extramedullary hematopoiesis in the sinusoids (Figure 5b , panel E). Moreover, their hepatocytes had small cytoplasmic vacuoles consistent with microvesicular lipidosis (Figure 5b , panel E). Note, these changes were similar to CCl 4 -treated MYC OFF mice that exhibited diffuse liver damage consistent with lobular postnecrotic collapse (Figure 5b , panel I). Also note that despite these distinct histological abnormalities in the liver, all MYC OFF mice remained comparable on a gross level (tumor-free, see above and Supplementary Table S1 ). Previously, we have shown that MYC-induced tumorigenesis in the adult murine liver is associated with MYC acquiring the ability to induce mitotic division of hepatocytes. 8 We speculated that shRNAs, by causing hepatoxicity, were inducing compensatory proliferation and mitotic cellular division. Indeed, we found a marked increase in cell proliferation in anti-p53-or sAg25-shRNA-injected MYC OFF mice as compared to untreated MYC OFF controls (Figure 6a , compare panels C/E to A, and MYC is thought to contribute to tumorigenesis by functioning as a transcription factor and inducing genes involved in cellular proliferation and growth. 3, [22] [23] [24] [25] [26] Cyclin B1, a key gene involved in the initiation of mitotic entry, is a direct transcription target of c-MYC. 24, 26 To determine whether MYC's ability to promote proliferation and tumorigenesis is related to its ability to induce cyclin B1, we used quantitative real-time PCR to measure cyclin B1 expression in our cohorts (Figure 6c) . Compared to the corresponding MYC OFF groups, anti-p53-and sAg-25-shRNAinjected MYC ON mice exhibited a three-to fivefold increase in cyclin B1 mRNA, respectively (Figure 6c) , that corresponded to the similar changes in cellular proliferation (Figure 6a,b) . Note that CCl 4 treatment similarly induced an increase in Ki67 and cyclin B1 mRNA levels that was potentiated in MYC ON mice. In contrast, cyclin B1 mRNA levels were neither elevated in MYC ON mice treated with the nontoxic hAAT-19 shRNA, nor in untreated mice, compared to the respective MYC OFF groups (Figure 6c) . Notably, we did not observe the induction of the S phase regulator cyclin D1 (data not shown). Our results suggest that when MYC is overexpressed in conjunction with toxic shRNAs, it is more capable of transactivating genes involved in mitotic regulation in the adult liver. Accordingly, differences in cyclin B1 expression could, in part, explain the increased hepatocyte proliferation observed upon shRNA treatment, and particularly in the presence of MYC overexpression.
We considered there were two possible mechanisms by which hepatic shRNA/MYC coexpression had caused the observed accelerated liver tumorigenesis, as depicted in Figure 7a : either the shRNAs had functionally cooperated with MYC in the same cell and enhanced MYC's proliferative potential, or, alternatively, they were inducing tumorigenesis indirectly, most likely through general cytotoxicity that nonspecifically increased hepatocyte proliferation. Accordingly, the tumors would have originated either from cells initially transduced with the AAV vectors, or nontransduced cells that started to proliferate following local hepatocyte death. Both possibilities were compatible with our observation that there was a loss of AAV/shRNA vector genomes in the tumors (Figure 3b ) that would have resulted from either cell division (model 1) or cell death (model 2). To experimentally distinguish the two options, we first directly examined whether shRNAs could cooperate with MYC to enhance the proliferative state of liver cells. In cultured human cells stably expressing MYC, we found that the two anti-p53 shRNAs yielded a 70-80% drop in mitotic indexes, compared to about 40% in MYC-negative control cells (Figure 7b,c) . Our results thus suggested that toxic shRNAs negatively impact the ability of MYC to induce cellular proliferation, arguing against the first model in Figure 7a .
We next studied whether MYC vice versa also interacted with the shRNAs and potentially increased their cytotoxicity, in line with our alternative second model. In fact, when we transfected MYC-negative or -positive cells with Renilla luciferase and either prevalidated specific or irrelevant control shRNAs, we observed an increase in target silencing with the anti-Renilla shRNAs in the presence of MYC (Figure 7d) , most notably at the low shRNA dose. MYC is known to transactivate RNA pol III promoters. [27] [28] [29] [30] Indeed, we found that the increase in target knockdown was related to a boost in shRNA expression from our U6-shRNA plasmids (Figure 7e) . We concluded that MYC expression can enhance shRNA levels and activity and thereby directly increase shRNA cytotoxicity, which in turn accelerated tumorigenesis in our mice (Figure 7a, model 2) .
Based on our prior findings that shRNA overexpression can saturate components of the cellular RNAi machinery and cause global miRNA dysregulation, 16 we examined the miRNA expression profiles in the various livers. The representative data in Figure 8 confirm that multiple miRNAs were dysregulated following anti-p53 vector infusion, in a dose-, time-, and MYCdependent manner. One notable example included several let7 miRNA family members whose expression transiently increased following low dose treatment. At the same shRNA dose, other miRNAs, such as miR-875-3p, -677 and -690, were specifically downregulated in MYC ON/anti-p53 mice at day 7, but not at earlier timepoints, nor in MYC OFF mice, nor in any controls. Our observation of miRNA dysregulation particularly in the presence of MYC further supports our model that MYC potentiated adverse shRNAs effects on cell survival (Figure 7a , model 2). Note that the same miRNAs were also downregulated in mice treated with the higher (lethal) shRNA vector dose (2 × 10 11 ) regardless of MYC, further supporting the synergistic cytotoxic effect of low-dose shRNA and MYC coexpression. Interestingly, at the nonlethal shRNA dose, an additional large miRNA set was concurrently upregulated in mice receiving anti-p53 or sAg-25 shRNA (Figure 8, four right lanes, let7a and below) . In contrast, numerous other miRNAs were exclusively downregulated in mice treated with the same dose of anti-p53 vector (Figure 8 , lanes 3/4 from right, miR-805 and up), perhaps suggesting a direct or indirect effect of p53 knockdown on their expression. The observation that miR-805 was downregulated in nearly all mice treated with the anti-p53 shRNA, regardless of dose, time point, or MYC, may imply a previously unknown key role of this particular miRNA in the p53 pathway, that will require further investigation.
dIscussIon
Our study is the first to reveal the potential carcinogenic properties that intracellularly expressed shRNAs can exert in the adult liver. The most likely explanation for our unexpected findings is that shRNAs, even at low doses not previously associated with morbidity or mortality in normal mice, can have subtle albeit significant hepatoxic effects that facilitate the ability of a potent oncogene, such as MYC, to induce cellular proliferation and thereby neoplasia.
Our conclusion is supported by a variety of new observations in this study, as well as by previously reported data (Supplementary Figure S1) . First, four independent shRNAs against three different targets accelerated the onset of MYC-dependent HCC, as evidenced by typical pathological and histological changes. Two of the shRNAs (sAg-25, hAAT-25) were irrelevant to HCC, the murine liver or p53, strongly implying a common and general carcinogenic shRNA effect. Second, under conditions of MYC overexpression, they were highly comparable to CCl 4 (a potent liver carcinogen causing centrilobular necrosis and liver regeneration [31] [32] [33] ) in their ability to accelerate HCC. In fact, CCl 4 -treated MYC ON mice developed tumors with a latency of onset that was identical to the toxic shRNAs. Also, both CCl 4 and shRNAs induced an increase in Ki67-positive hepatocytes and cyclin B1 expression that was even more pronounced during MYC overexpression. We conclude that shRNAs can create a hepatic context of constant mitotic division that promotes MYC-induced HCC, similar to a known carcinogen. Third, our observations are consistent with prior models that hepatocytes gain susceptibility to neoplastic transformation under circumstances causing organ regeneration and cellular proliferation, in particular liver damage. [34] [35] [36] [37] [38] [39] [40] Moreover, our data are congruent with our previous report that MYC overexpression induces HCC only when the hepatocytes are already rapidly proliferating, such as during early mouse development or after partial hepatectomy. 8 MYC is well known to cooperate with carcinogens to induce HCC. 41, 42 Generally, it is thought that these agents cause liver damage, and that the resulting compensatory hepatocyte proliferation cooperates with MYC to induce tumorigenesis. Similarly, we think it is likely that toxic shRNAs are cooperating with MYC by inducing liver cell death and thereby promoting a cellular state more permissive to MYC for inducing malignant transformation. Hence, we propose that shRNAs initially exert a toxic effect in the liver, killing numerous dispersed transduced cells, and stimulating mitotic division of adjacent hepatocytes (model 2 in Figure 7a ). Even if some of the liver cells originally still contained AAV vectors, the viral DNA was then lost during cell division due to the episomal nature of AAV genomes in the liver. Our explanation is consistent with our previous report that sublethal shRNA doses can trigger liver damage and repopulation in normal mice. 16 Yet, a crucial difference from what we describe here is that the present livers were additionally expressing a potent oncogene. A critical combination of repopulation signal (shRNA-induced cell death and liver injury) and high proliferation potential (MYC overexpression) conceivably promoted the observed accelerated tumorigenesis. table s1 ). Also note the many differences between the MYC ON and OFF groups for a given shRNA, as well as the specific and MYCindependent response (decrease) of miR-805 to p53 RNAi (see text for details). HCC, hepatocellular carcinoma; miRNA, microRNA; RNAi, RNA interference; sAg, surface antigen; shRNA, short hairpin RNA.
We recognize that, as an alternative possibility, the vectorexpressed shRNAs could have interacted directly with MYC within the same cells to promote their malignant transformation (model 1 in Figure 7a) . We thus attempted to determine whether the introduction of shRNAs into MYC overexpressing cells increased their proliferation. Instead, we observed a significant decrease in the mitotic index suggesting that they are toxic to cells and generally inhibit cellular proliferation. Along this line, we noted marked global changes in hepatic miRNA expression profiles upon microarray analyses of shRNA vector-treated mouse livers that were even more pronounced in animals coexpressing MYC. Although we cannot experimentally rule out here that this miRNA dysregulation directly influenced the ability of MYC to induce tumorigenesis, we consider it more likely that it resulted in more general hepatocyte toxicity and death. The diverse pattern of miRNA up-or downregulation we observed appears to indicate a global interference of shRNA expression with the hepatic miRNA machinery, that could result in toxicity, as we have proposed before. 16 Of note, more specific modulation of miRNAs that does not induce hepatoxicity could have therapeutic benefit in liver tumorigenesis, as for example has been shown recently for the AAV-8-mediated delivery of mir-26a. 43, 44 Altogether, our data thus strongly support model 2 in Figure 7a , according to which shRNA-induced hepatoxicity and subsequent changes in the hepatic microenvironment indirectly cooperated with MYC overexpression to induce tumorigenesis. Intriguingly, our data suggest that shRNA-induced hepatoxicity may have concurrently stimulated oval cell expansion and proliferation. Histological analyses yielded evidence for the development of neoplastic foci near the periportal areas, implying a critical role for less mature hepatocytes or oval cells in shRNA/ MYC-induced tumorigenesis, as described previously. 38, 45 These less mature hepatocytes are probably poor AAV-8 targets and were thus initially likely not infected by our shRNA vectors. Collectively, poor transduction of proliferative oval cells, death of initially well transduced hepatocytes, and propagation of, and subsequent liver repopulation with, less or untransduced other hepatocytes can readily explain our observation of carcinogenic shRNA effects.
The findings and model reported here have important implications for the future development and use of shRNAs as human therapeutics. Multiple prior reports have documented dose-and sequence-dependent adverse shRNA effects on normal cells, and had suggested diverse underlying mechanisms, including saturation of the miRNA machinery and off-targeting. 16, [46] [47] [48] Yet, we are the first to demonstrate that even marginal shRNA expression can have a marked effect, in particular on the susceptibility to tumorigenesis. In a normal adult liver, the low shRNA doses used here would induce mild hepatic damage, followed by compensatory hepatocyte proliferation, without a clinical phenotype. In contrast, as shown here, the combination with an active oncogene can drastically alter the outcome, by accelerating tumorigenesis and causing mortality. Intriguingly, the carcinogenic effects of shRNA-induced liver toxicity were only uncovered in the presence of MYC oncogene overexpression in our mice, making them highly susceptible to even minimal cell damage. A particularly interesting finding in this context was that MYC can stimulate shRNA expression from U6 promoters, as used in our vectors. We conclude that MYC actually exerted a synergistic dual effect in our mice, both boosting shRNA expression and thus concurrently increased cytotoxicity and death of hepatocytes, and then stimulating proliferation of adjacent nontransduced liver cells (perhaps including oval cells, as discussed above) and thereby ultimately accelerated tumorigenesis. In this respect, our mouse model system represents a highly sensitive and straightforward in vivo assay for future screens of toxic or tumorigenic effects of new shRNAs. Concurrently, our mice provide a new small animal model to further define the underlying molecular and cellular mechanisms of shRNA-induced cellular toxicity. It will also be interesting to determine whether shRNAs will have carcinogenic effects in other tissues, and in combination with further oncogenes.
Our study dramatically illustrates the necessity to design and use shRNA sequences and vectors with the lowest possible degree of toxicity or carcinogenicity. We and others have recently made marked efforts in this direction through the development of tissue-specific (liver) shRNA expression cassettes 20 or our selection of more efficient and specific viral vector capsids for RNAi delivery. 49 We thus believe that the safe introduction of RNAi therapeutics into humans remains a highly realistic goal.
MAterIAls And MetHods
Transgenic mice. The TRE-MYC transgenic line has been described previously. 9 The LAP-tTA transgenic line was kindly provided by Hermann Bujard. 10 MYC expression was activated by removing doxycycline treatment (100 µg/ml) from the drinking water of mice transgenic for both TRE-MYC and LAP-tTA. doses were lethal in all mice, consistent with our previously reported findings that some shRNAs can be highly toxic in the liver. 16 All further analyses were thus performed on mice injected with the lowest (2 × 10 10 ) vector dose. Mice were injected intraperitoneally with CCl 4 (diluted in mineral oil, 1 µl/g of mouse) (Sigma-Aldrich, St Louis, MO) two times a week every week until killed. Mice were monitored daily and killed when moribund with tumor burden. During necropsy, liver tissues were saved by snapfreezing in liquid nitrogen. Liver tissues for histological analyses were fixed in 10% buffered formalin for 24 hours and then transferred to 70% ethanol until paraffin embedding. Tissue sections 4-µm thick were cut from paraffin-embedded blocks, placed on glass slides and stained with hematoxylin and eosin. Paraffin embedding and staining were performed by the Stanford Histology Core (Stanford, CA). All procedures were approved by the Animal Care Committee at Stanford University (Stanford, CA).
Design and analyses of plasmids for shRNA expression. A set of 10 different shRNAs directed against murine p53 was selected using the Invivogen (San Diego, CA) "siRNA Wizard" online tool (www.sirnawizard.com). Design criteria were: (i) 19 or 21 nucleotide (nt) stem lengths, (ii) sense strand (beginning with a G) located before the antisense strand, (iii) both strands separated by a seven nt loop (5′ TCA AGA G 3′), and (iv) no significant homology to the mouse genome. The following sequences were chosen (shown are the sense strands, with target region and stem length in brackets; see also shRNAs Can Act as Carcinogens in the Adult Liver mer), P5 5′ GGC CAT CTA CAA GAA GTC ACA 3′ (nt 471-491, 21 mer), P6 5′ GAC CTA TCC TTA CCA TCA TCA 3′ (nt 737-757, 21 mer), P7 5′ GGA GCT GAA TGA GGC CTT AGA 3′ (nt 1,017-1,037, 21 mer), P8 5′ GCT GAA TGA GGC CTT AGA GTT 3′ (nt 1,020-1,040, 21 mer), P9 5′ GTA CTC TCC TCC CCT CAA T 3′ (nt 366-384, 19 mer), P10 5′ GTA CAT GTG TAA TAG CTC C 3′ (nt 696-714, 19 mer). All shRNAs were purchased as complementary oligonucleotides (IDT-DNA, Coralville, IA), annealed, cloned into our AAV vector plasmid, 16 and eventually verified by DNA sequencing. In the resulting constructs, the shRNAs were expressed from a human U6 promoter and terminated by a stretch of five Ts. All other shRNAs used in this study (hAAT-19, hAAT-25, sAg-25) have been reported before 16 and were expressed from an identical backbone. An exception are the shRNAs against Renilla luciferase that will be reported elsewhere (N. Schürmann, L.S. Wang, E. Wiedtke, and D. Grimm, personal communication). To evaluate shRNA efficacy, murine p53 complementary DNA was first PCR-amplified from a commercial mouse liver complementary DNA library (BD Clontech, Palo Alto, CA), using as primers 5′ GAC CT TCTAGA ATG ACT GCC ATG GAG GAG TCA CAG 3′ and 5′ CTT GG GTCGAC TCA GTC TGA GTC AGG CCC CAC TTT C 3′. The primers contained XbaI or SalI restriction sites (underlined), allowing subcloning into plasmid pTRUF2 (bringing the p53 complementary DNA under the control of a cytomegalovirus promoter). 50 Human Huh-7 liver cells were then co-transfected with equal amounts of p53 expression plasmid and each shRNA construct. Three days later, total protein extracts were prepared and analyzed via western blotting, using a rabbit polyclonal antibody (ab2433-1; Abcam, Cambridge, MA) for p53 detection. The psiCheck-2 plasmid expressing Renilla luciferase (plus firefly luciferase for normalization) and reagents for luciferase assays were purchased from Promega (Mannheim, Germany). Assays to determine MYC/ shRNA interactions were performed in human wild-type HaCat or stably MYC-transfected HaCat cells.
Production of shRNA-expressing AAV vectors. All vector genomes were packaged into capsids from AAV-8, based on this particular isolate's superior performance in mouse liver. 18 Recombinant viruses were generated via a standard triple-transfection method, purified using cesium chloride density gradient centrifugation and titered by dot blot, as described before. 16 Typical vector particle yields were 5 × 10 12 /ml or higher.
Southern and northern blot analysis. Extraction of genomic DNA from mouse liver and analysis of persisting AAV vector genomes were performed as described previously, 16 using a 1.7-kb probe against a sequence conserved in all shRNA vector genomes. Northern blots for shRNA detection were performed as described previously.
16
RNA isolation and complementary DNA preparation. Total cellular RNA was isolated from snap-frozen liver tissue using the RNeasy kit (Qiagen, Valencia, CA) following the manufacturer's protocol. RNA was quantified using spectrophotometric OD 260 measurements and reverse transcribed using Oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA).
Quantitative real-time-PCR. Quantitative real-time-PCR was performed on the ABI Prism 7700 Sequence detection system (Applied Biosystems, Foster City, CA) using the SYBR Green PCR Master Mix (Applied Biosystems). PCRs were performed in triplicate in a final volume of 20 µl. Primer sequences were as follows: p53 forward 5′ TCA CCT CAC TGC ATG GAC GA 3′, p53 reverse 5′ ACT CGG AGG GCT TCA CTT GG 3′, cyclin B1 forward 5′ ACT TCC TCC GTA GAG CAT C 3′, cyclin B1 reverse 5′ GCA GAG TTG GTG TCC ATT C 3′, ubiquitin forward 5′ AGC CCA GTG TTA CCA CCA AG 3′, ubiquitin reverse 5′ ACC CAA GAA CAA GCA CAA GG 3′. Thermal cycling conditions were: 95 °C for 10 minutes, followed by 40 cycles of 95 °C for 15 seconds, 57 °C for 30 seconds, 72 °C for 30 seconds, and a dissociation stage consisting of 95 °C for 15 seconds, 60 °C for 15 seconds, and 95 °C for 15 seconds. p53 mRNA and cyclin B1 mRNA expression levels were normalized to ubiquitin expression levels and expressed relative to normal livers.
Proliferation assay. Ki67 expression was examined by immunofluorescence using a mouse antihuman Ki67 monoclonal antibody (BD Biosciences, San Jose, CA) and the vector mouse on mouse (M.O.M.) basic kit (Vector Laboratories, Burlingame, CA). Slides were deparaffinized in xylene and rehydrated in a graded series of ethanols, followed by antigen retrieval in a microwave for 14 minutes in vector antigen unmasking solution (H-3300; Vector Laboratories, Burlingame, CA), and incubated in 100 mmol/l glycine two times for 8 minutes to reduce fluorescent background. They were then incubated in avidin followed by biotin for 10 minutes each using the Dako biotin blocking system (DAKO, Carpinteria, CA), and subsequently Quantitation of mitotic indexes. Wild-type or stably MYC-expressing HaCat cells were transfected with shRNA expression plasmids and 48 hours later fixed with 4% paraformaldehyde at room temperature for 30 minutes. They were then permeabilized using 0.2% triton (30 minutes at room temperature), washed three times with 1× PBS and subsequently incubated for 30 minutes with 1× PBS/5% fetal bovine serum, to block unspecific binding sites. This solution was aspirated and the cells were incubated overnight at 4 ºC with a mouse monoclonal antibody against histone 3 phospho-serine 10 (PH3, diluted 1:500 in 1× PBS/5% fetal bovine serum) (New England Biolabs, Frankfurt, Germany). PH3 is a marker for dividing nuclei, as it correlates with chromosome condensation during mitosis. Unbound antibody was then removed by washing the cells three times with 1× PBS, prior to staining with secondary Alexa Fluor 488-coupled anti-mouse immunoglobin G antibody (diluted 1:500) for 2 hours at room temperature. Moreover, Hoechst fluorescent DNA binding dye was added to identify individual nuclei/cells. The cells were next washed again three times in 1× PBS and left in wash buffer for subsequent automatic data acquisition. Fluorescence was measured in an Olympus microscope (Olympus, Center Valley, PA), using appropriate excitation and emission filters, and numbers of total nuclei and mitotic cells were recorded for each individual well. Automated image segmentation was then performed via voronoi-like watershed transformation, using image analysis software kindly provided by Christoph Sommer (Interdisciplinary Center for Scientific Computing, Heidelberg University, Heidelberg, Germany). Finally, the fraction of cells in mitosis (mitotic index) was calculated by dividing numbers of PH3-positive cells by total nuclei counts.
Microarray analysis of miRNA expression profiles. MiRNA was extracted using a miRNeasy mini kit (Qiagen) from livers of mice in which transgenic MYC was expressed together with various shRNAs. In addition, miRNA was extracted from livers of mice that were AAV-treated but in which transgenic MYC was silent, to determine MYC-versus shRNAdependent effects. MiRNA was Cy3-labeled and hybridized to miRCURY LNA miRNA arrays according to manufacturer's instructions (Exiqon, Woburn, MA). Cy5-labeled miRNA from wild-type, untreated liver was hybridized together with experimental miRNA for normalization. Arrays were scanned and images acquired at 556 nm and 656 nm to detect Cy3-and Cy5-labeled miRNA, respectively. Resulting data were analyzed by suPPleMentArY MAterIAl Figure S1 . In vivo outcomes of AAV/shRNA infusion into adult mice. Table S1 . Summary of in vivo results obtained with various AAV/ shRNA vectors or control treatments.
